Xilio Therapeutics (XLO) Total Current Liabilities (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Total Current Liabilities data on file, last reported at $43.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 9.82% year-over-year to $43.0 million; the trailing twelve-month figure through Mar 2026 stood at $43.0 million (down 9.82% YoY), and the FY2025 full-year result was $56.3 million, up 106.42% from the prior year.
• Total Current Liabilities declined to $43.0 million in Q1 2026, from $56.3 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $56.4 million in Q3 2025 to a low of $12.2 million in Q1 2022.
• A 5-year average of $30.9 million and a median of $27.3 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities decreased 24.44% in 2023 and jumped 137.16% in 2024, its largest moves.
• Tracing XLO's Total Current Liabilities over 5 years: stood at $21.1 million in 2022, then declined by 24.44% to $16.0 million in 2023, then jumped by 70.84% to $27.3 million in 2024, then soared by 106.42% to $56.3 million in 2025, then dropped by 23.66% to $43.0 million in 2026.
• Business Quant data shows XLO's Total Current Liabilities at $43.0 million in Q1 2026, $56.3 million in Q4 2025, and $56.4 million in Q3 2025.